🔗 Share this article

A high-ranking medical officer was taken off from participation in an major clinical trial on gender-affirming medication after accusations of bias came to light.

Alleged Involvement Resulted in Trial Pause

As reported by media coverage, Professor Jacob George, a chief medical director for the regulatory agency, expressed concerns which caused the pausing of the national research initiative during early 2024.

The authority declared this weekend that the professor would recuse himself of any role in the study after gender-critical social media posts made in the past came to light.

Nature of Social Media Comments

In a post, he referred to author J.K. Rowling being an asset in modern society.” Separately, he commented how the rejection of fundamental scientific reality was troubling” in relation to questions about a elite boxer’s gender.

The agency said that although the posts occurred prior to his appointment, the official was taken off of oversight with the study as an abundance of caution.

Particulars Regarding the Paused Pathways Trial

This clinical study, that aimed to study the influence from puberty blockers on young people uncertain about their gender, was scheduled to begin signing up volunteers in January.

But, the trial was paused during the following month after its medicines regulator raised worries over the safety of children and young people taking part.

• The youngest volunteers were expected to be ten to eleven for assigned female at birth while 11 to 12 among assigned male at birth.
• Its study leadership noted at the time how the rigorous screening process suggested those enrolled would probably be of a higher age.
• However, the regulator have since recommended the lowest age requirement ought to be 14 because of the unknown danger” for “long-term physical side effects.”

This clinical trial aimed to recruit around 226 youths over the coming several years.

Background and a Independent Report

The study was initiated subsequent to an urging from the Cass review into children’s gender identity services, which concluded that the standard of the evidence suggesting to show the benefits from such medication for children with gender dysphoria was “poor.”

Dr Hilary Cass, who chaired that inquiry, had earlier commented her report revealed a notably limited evidence base” supporting the benefits of such treatments.

She noted, since there are clinicians, young people as well as parents that believe strongly in the positive outcomes, a trial was the sole method forward to make sense of the situation.”

Medical Concern of the Action

Dr Max Davie, a child health specialist, stated there was no strong medical rationale to suspend the study.

“The tweets by Prof George provide a clear indication of his own opinions on the topic,” Dr. Davie remarked. “The professor is free to possess whatever views on gender identity he wishes, but what is improper is permit these opinions to influence the fulfilment of his official role.”

He concluded: “It must be understood, there exists no definitive research justification to pause this study. Although the professor’s individual beliefs is not the sole potential reason of the MHRA’s unexpected change of position, it is the single factor for which we have evidence.”

Regulator Statement Regarding Future Actions

A regulatory representative said: “With every clinical trials, the MHRA’s top priority is the protection and wellbeing of the trial participants. In line with this duty, complex clinical trials remain continuously being monitored while the MHRA keeps an ongoing conversation alongside trial sponsors.”

“The MHRA have leading medical, scientific and regulatory specialists who work in a cross-functional team to make evidence-based rulings on medical research. These individuals shall persist to work alongside the organizers to navigate the future path constructively.”

“Following the discovery of online posts made before he took up his role, Professor Jacob George has been recused of any additional participation on this clinical trial as a precaution.”